Overcoming barriers and shaping the future: Challenges and innovations in nucleic acid therapies for Glioblastoma

Dec 12, 2025Advanced drug delivery reviews

Challenges and new advances in genetic material treatments for glioblastoma

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Nucleic acid-based therapies may enhance treatment for glioblastoma by targeting oncogenic pathways.

Conventional therapies for glioblastoma show limited effectiveness due to tumor heterogeneity and the blood-brain barrier.
Nucleic acid-based therapies include various forms such as small interfering RNA and CRISPR systems, which may modify genetic pathways.
Effective delivery of these therapies is a significant challenge that impacts their clinical success.
Innovative delivery systems like liposomes and lipid nanoparticles have shown promise in enhancing therapeutic precision.
Preclinical advancements in multifunctional and targeted carriers indicate strong potential for future clinical applications.

AI simplified

Glioblastoma (GBM) is the most aggressive and treatment-resistant primary brain tumor in adults. Conventional therapies offer limited benefit due to the tumor's heterogeneity, invasive nature, and the presence of the blood-brain barrier, which restricts therapeutic access. Nucleic acid (NA)-based therapies, including small interfering RNA, microRNA, antisense oligonucleotides, splice-switching oligonucleotides, and CRISPR-based systems, have emerged as promising tools to modulate oncogenic pathways and overcome resistance mechanisms at the genetic level. However, effective delivery remains the primary challenge in translating these therapies into clinical success. This review examines the current landscape of NA-based strategies for GBM, with a focus on innovative delivery systems designed to navigate biological barriers and enhance therapeutic precision. We highlight clinical progress made with nanocarrier platforms such as liposomes, lipid nanoparticles, and exosome-based systems, and evaluate their safety, specificity, and delivery efficiency. Additionally, we discuss the most promising preclinical advances, including multifunctional, targeted, and stimuli-responsive carriers, that demonstrate strong potential for clinical translation. Our analysis underscores that the therapeutic efficacy of NA approaches in GBM is inseparable from the sophistication of their delivery platforms. Moving forward, the integration of rationally designed carriers with gene-targeted payloads holds the key to unlocking the full potential of precision medicine in GBM.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Overcoming barriers and shaping the future: Challenges and innovations in nucleic acid therapies for Glioblastoma

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief